/ PORTFOLIO Boston, MAAtalanta Therapeutics is a biotechnology company dedicated to finding solutions for intractable diseases of the central nervous system. Utilizing its novel platform of divalent small interfering RNA (di-siRNA), Atalanta is initially focused on advancing two lead programs through clinical proof-of-concept: KCNT1 (ATL-201) to...
/ PORTFOLIO /*! elementor - v3.21.0 - 08-05-2024 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAEngrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. The company is committed to rapidly advancing its innovative, precision-targeted therapeutics for the...
/ PORTFOLIO /*! elementor - v3.17.0 - 25-10-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WABonum is a biopharma company developing immuno-oncology drugs exclusively active within the tumor micro-environemnt.BONUMTX.COM © Copyright RiverVest® All Rights Reserved....
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAAvalyn is a biopharma company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The lead asset is inhaled pirfenidone (Aerodone™) for the treatment of...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Boston, MAXilio is an oncology company developing highly-potent, tumor-selective immunotherapies to improve patient outcomes. With an anti-CTLA4 antibody as validation, the company’s technology is also being applied to cytokines, which currently have limited or...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Seattle, WAOncoResponse is leveraging a proprietary human antibody platform to discover novel targets and identify fully-human monoclonal antibodies as therapeutics for the treatment of cancer, potentially extending cures to patients who otherwise would not...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOOxaluRx is a preclinical company developing a small molecule, oral therapy to treat primary hyperoxaluria, a rare orphan metabolic disease. This rare form of hyperoxaluria is due exclusively to a genetic defect...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} St. Louis, MOWugen is developing a novel chimeric antigen receptor (CAR-T) therapy platform for T-cell malignancies. Wugen’s state-of-the-art gene editing and CAR-T cell technology enable “off-the-shelf” therapies that would avoid rejection by the recipient....
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Portland, ORSparrow Pharmaceuticals was founded to spare patients the ravages of corticosteroids. Leveraging underappreciated scientific insights into steroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Carlos, CAGlycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes,...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Francisco, CABluejay Therapeutics develops innovative cures for infectious diseases. The first target indication is chronic HBV infection (CHBV). Bluejay has in-licensed three promising assets from Novartis that use different mechanisms to contribute to...